ProCE Banner Activity

COSMIC-311 Final Analysis: Phase III Trial of Cabozantinib vs Placebo in Radioiodine-Refractory Differentiated Thyroid Cancer After VEGFR TKI

Slideset Download
Conference Coverage
In this final analysis of the landmark COSMIC-311 trial, cabozantinib maintained a significant PFS benefit vs placebo in patients with radioiodine-refractory/-ineligible differentiated thyroid cancer after prior VEGFR TKI therapy.

Released: September 29, 2021

Expiration: September 28, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc